Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group

Sharlene Gill, Daniel J. Sargent

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Adjuvant Colon Cancer Endpoints (ACCENT) Group is an international, collaborative, individual-patient data analysis now including 20,898 patients enrolled in 18 adjuvant therapy trials for resected stage II and stage III colon cancer, spanning the years 1977 to 1999. This article discusses the proceedings published and presented since the inception of the ACCENT Group in 2003, which notably include the evaluation of 3-year disease-free survival as an acceptable end point in adjuvant studies, particularly in stage III colon cancer, and an improved understanding of the time-dependent patterns of failure and benefi t of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)155-159
Number of pages5
JournalCurrent Colorectal Cancer Reports
Volume4
Issue number3
DOIs
StatePublished - Jul 2008

Fingerprint

Colonic Neoplasms
Therapeutics
Disease-Free Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Cite this

Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer : Review of the ACCENT collaborative group. / Gill, Sharlene; Sargent, Daniel J.

In: Current Colorectal Cancer Reports, Vol. 4, No. 3, 07.2008, p. 155-159.

Research output: Contribution to journalArticle

@article{f25d4f34e7b64b509ee9f4a5508cbe82,
title = "Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group",
abstract = "The Adjuvant Colon Cancer Endpoints (ACCENT) Group is an international, collaborative, individual-patient data analysis now including 20,898 patients enrolled in 18 adjuvant therapy trials for resected stage II and stage III colon cancer, spanning the years 1977 to 1999. This article discusses the proceedings published and presented since the inception of the ACCENT Group in 2003, which notably include the evaluation of 3-year disease-free survival as an acceptable end point in adjuvant studies, particularly in stage III colon cancer, and an improved understanding of the time-dependent patterns of failure and benefi t of adjuvant therapy.",
author = "Sharlene Gill and Sargent, {Daniel J.}",
year = "2008",
month = "7",
doi = "10.1007/s11888-008-0025-y",
language = "English (US)",
volume = "4",
pages = "155--159",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer

T2 - Review of the ACCENT collaborative group

AU - Gill, Sharlene

AU - Sargent, Daniel J.

PY - 2008/7

Y1 - 2008/7

N2 - The Adjuvant Colon Cancer Endpoints (ACCENT) Group is an international, collaborative, individual-patient data analysis now including 20,898 patients enrolled in 18 adjuvant therapy trials for resected stage II and stage III colon cancer, spanning the years 1977 to 1999. This article discusses the proceedings published and presented since the inception of the ACCENT Group in 2003, which notably include the evaluation of 3-year disease-free survival as an acceptable end point in adjuvant studies, particularly in stage III colon cancer, and an improved understanding of the time-dependent patterns of failure and benefi t of adjuvant therapy.

AB - The Adjuvant Colon Cancer Endpoints (ACCENT) Group is an international, collaborative, individual-patient data analysis now including 20,898 patients enrolled in 18 adjuvant therapy trials for resected stage II and stage III colon cancer, spanning the years 1977 to 1999. This article discusses the proceedings published and presented since the inception of the ACCENT Group in 2003, which notably include the evaluation of 3-year disease-free survival as an acceptable end point in adjuvant studies, particularly in stage III colon cancer, and an improved understanding of the time-dependent patterns of failure and benefi t of adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=84857429522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857429522&partnerID=8YFLogxK

U2 - 10.1007/s11888-008-0025-y

DO - 10.1007/s11888-008-0025-y

M3 - Article

AN - SCOPUS:84857429522

VL - 4

SP - 155

EP - 159

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -